Head and Neck Cancer Therapeutics Market Share

North America Market Statistics

North America in head and neck cancer therapeutics market is estimated to hold over 37.5% revenue share by the end of 2037. The market is growing due to government support for the development of the medical industry, favorable reimbursement policies, and increased awareness of diseases, increased R&D, and easy access to advanced healthcare facilities.

The head and neck cancer therapeutics market is expanding in the U.S. due to the high incidence of the disease, active research and development, quick adoption of novel treatments, and a strong healthcare system. Furthermore, the patient base needing specialized therapies has expanded due to the increasing frequency of oropharyngeal malignancies, one of the most common head and neck cancers, which is linked to HPV. The U.S. Cancer Statistics estimates that between 2017 and 2021, there were 47,984 new HPV-related malignancies recorded in the country, with 26,280 cases affecting females and 21,704 cases affecting males.

The Government of Canada provides funding for medical research, especially cancer research, fostering innovation in head and neck cancer therapy and displaying opportunities for novel medications and treatment approaches. For instance, the Canadian Institutes of Health Research CIHR invested more than USD 1 billion on cancer research between 2016 and 2021.

APAC Market Analysis

Asia Pacific will encounter huge growth for the head and neck cancer therapeutics market during the forecast period. The market growth is anticipated to be fueled by the aging population and the growing usage of immunotherapeutic medications such as Nivolumab (Opdivo) and Pembrolizumab (Keytruda) for treating different forms of HNC. According to the United Nations Population Fund, the number of individuals in the region who are 60 or older will more than double to 1.3 billion by 2050.

China is one of the largest pharmaceutical markets globally. A robust healthcare system, a highly skilled labor force, and a robust and changing consumer health market are just a few factors contributing significantly to the nation's head and neck cancer therapeutics industry growth.

The need for cutting-edge cancer therapies is fueled by India's rise as a major destination for medical tourism, where patients come for reasonably priced and excellent cancer treatment. According to the Ministry of Tourism, from 5,244 in 2016 to 8,537 in 2019, the number of patients from outside rose, and the medical tourism industry reached USD 6 billion in 2019.